Rigel Pharmaceuticals - RIGL Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $5.81
  • Forecasted Upside: 495.42%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.98
▲ +0.0262 (2.76%)

This chart shows the closing price for RIGL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Rigel Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RIGL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RIGL

Analyst Price Target is $5.81
▲ +495.42% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Rigel Pharmaceuticals in the last 3 months. The average price target is $5.81, with a high forecast of $15.00 and a low forecast of $1.25. The average price target represents a 495.42% upside from the last price of $0.98.

This chart shows the closing price for RIGL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 investment analysts is to moderate buy stock in Rigel Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00Low
6/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00Low
5/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00Low
3/7/2024CitigroupBoost TargetBuy ➝ Buy$3.00 ➝ $4.00Low
3/6/2024Cantor FitzgeraldBoost TargetNeutral ➝ Neutral$2.00 ➝ $3.00Low
3/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00Low
3/6/2024B. RileyReiterated RatingNeutral ➝ Neutral$1.25Low
2/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00Low
1/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00Low
12/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$15.00Low
8/2/2023HC WainwrightReiterated RatingBuy ➝ Buy$15.00Low
4/3/2023Piper SandlerReiterated RatingNeutral$2.00Low
3/9/2023CitigroupBoost TargetBuy$2.00 ➝ $3.00Low
3/8/2023HC WainwrightReiterated RatingBuy$15.00Low
12/2/2022CitigroupUpgradeNeutral ➝ BuyLow
11/4/2022BMO Capital MarketsLower TargetOutperform$4.00 ➝ $3.00Low
8/18/2022HC WainwrightBoost TargetBuy$7.00 ➝ $15.00Low
8/16/2022Piper SandlerBoost TargetNeutral$1.00 ➝ $2.00Low
8/9/2022CitigroupBoost Target$1.50Low
6/9/2022BMO Capital MarketsLower Target$7.00 ➝ $3.00High
6/9/2022B. RileyLower TargetNeutral$4.00 ➝ $1.25High
6/9/2022CitigroupDowngradeBuy ➝ Neutral$7.00 ➝ $0.80High
6/8/2022Jefferies Financial GroupDowngradeBuy ➝ HoldHigh
6/8/2022Piper SandlerDowngradeOverweight ➝ Neutral$7.00 ➝ $1.00N/A
6/8/2022HC WainwrightLower TargetBuy$11.00 ➝ $7.00N/A
6/8/2022Cantor FitzgeraldDowngradeOverweight ➝ Neutral$6.00 ➝ $1.00N/A
3/23/2022B. RileyInitiated CoverageNeutral$4.00High
11/8/2021BMO Capital MarketsReiterated RatingBuy$8.00Low
9/28/2021HC WainwrightReiterated RatingBuy$11.00Medium
6/29/2021HC WainwrightReiterated RatingBuy$11.00Low
3/11/2021HC WainwrightReiterated RatingBuy$11.00Medium
2/18/2021HC WainwrightBoost TargetBuy$8.00 ➝ $11.00High
11/9/2020Cantor FitzgeraldReiterated RatingOverweightHigh
11/9/2020JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
8/6/2020CitigroupBoost TargetBuy$7.00 ➝ $8.00High
7/9/2020HC WainwrightReiterated RatingBuy$8.00Medium
5/27/2020JPMorgan Chase & Co.Lower TargetOverweight$7.00 ➝ $6.00Low
12/18/2019HC WainwrightReiterated RatingBuy$8.00Low
12/9/2019BMO Capital MarketsLower TargetOutperform$11.00 ➝ $8.00Low
10/18/2019Cantor FitzgeraldReiterated RatingOverweightLow
9/26/2019JPMorgan Chase & Co.Reiterated RatingOverweight$7.00High
9/23/2019HC WainwrightSet TargetBuy$8.00High
(Data available from 6/24/2019 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2023
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/26/2024
  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2024
  • 5 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/26/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 3 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/25/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/24/2024

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Rigel Pharmaceuticals logo
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $0.98
Low: $0.95
High: $0.99

50 Day Range

MA: $1.01
Low: $0.90
High: $1.22

52 Week Range

Now: $0.98
Low: $0.71
High: $1.73

Volume

42,620 shs

Average Volume

1,303,029 shs

Market Capitalization

$171.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04

Frequently Asked Questions

What sell-side analysts currently cover shares of Rigel Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on Rigel Pharmaceuticals in the last twelve months: B. Riley, Cantor Fitzgerald, Citigroup Inc., HC Wainwright, and StockNews.com.
View the latest analyst ratings for RIGL.

What is the current price target for Rigel Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Rigel Pharmaceuticals in the last year. Their average twelve-month price target is $5.81, suggesting a possible upside of 495.4%. HC Wainwright has the highest price target set, predicting RIGL will reach $15.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $1.25 for Rigel Pharmaceuticals in the next year.
View the latest price targets for RIGL.

What is the current consensus analyst rating for Rigel Pharmaceuticals?

Rigel Pharmaceuticals currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for RIGL.

What other companies compete with Rigel Pharmaceuticals?

How do I contact Rigel Pharmaceuticals' investor relations team?

Rigel Pharmaceuticals' physical mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company's listed phone number is (650) 624-1100 and its investor relations email address is [email protected]. The official website for Rigel Pharmaceuticals is www.rigel.com. Learn More about contacing Rigel Pharmaceuticals investor relations.